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Abstract: Inflammatory processes are crucial in atherosclerosis and atherothrombosis. This study aimed
to identify a cytokine-pattern that is associated with plaque-vulnerability or symptomatic state in com-
prehensively investigated patients with symptomatic (sCS) and asymptomatic carotid stenosis (aCS).
Twenty-two patients with sCS and twenty-four patients with aCS undergoing carotid endarterectomy
(CEA) were considered. A cytokine-panel was measured in plasma-specimens prior to surgery and at a
90 day follow-up. Doppler-ultrasound detecting microembolic signals (MES) in the ipsilateral middle cere-
bral artery was performed. Carotid plaques were analysed regarding histopathological criteria of plaque-
vulnerability and presence of chemokine receptor CXCR4. Correction for multiple comparisons and logis-
tic regression analysis adjusting for vascular risk factors, grade of stenosis, antithrombotic and statin pre-
treatment were applied. In sCS-patients higher plasma-levels of Fractalkine (CX<jats:sub>3</jats:sub>CL1),
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cells was more evident in sCS- compared to aCS-plaques and was associated with vulnerability-criteria. In
contrast, plasma-cytokine-levels were not related to CXCR4-expression or other vulnerability-criteria or
MES. However, in both groups distinct inter-cytokine correlation patterns, which persisted at follow-up
and were more pronounced in the sCS-group could be detected. In conclusion, we identified a distinct
cytokine/chemokine-network in sCS-patients with elevated and closely correlated mediators of diverse
functions.
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Distinct systemic cytokine 
networks in symptomatic 
and asymptomatic carotid stenosis
Ricarda D. Stauss1,8, Gerrit M. Grosse 1,8*, Lavinia Neubert2, Christine S. Falk3, 
Danny Jonigk2, Mark P. Kühnel2, Maria M. Gabriel1, Ramona Schuppner1, 
Ralf Lichtinghagen4, Mathias Wilhelmi5,6, Karin Weissenborn1,8 & Claudia Schrimpf6,7,8
Inflammatory processes are crucial in atherosclerosis and atherothrombosis. This study aimed to 
identify a cytokine-pattern that is associated with plaque-vulnerability or symptomatic state in 
comprehensively investigated patients with symptomatic (sCS) and asymptomatic carotid stenosis 
(aCS). Twenty-two patients with sCS and twenty-four patients with aCS undergoing carotid 
endarterectomy (CEA) were considered. A cytokine-panel was measured in plasma-specimens prior 
to surgery and at a 90 day follow-up. Doppler-ultrasound detecting microembolic signals (MES) 
in the ipsilateral middle cerebral artery was performed. Carotid plaques were analysed regarding 
histopathological criteria of plaque-vulnerability and presence of chemokine receptor CXCR4. 
Correction for multiple comparisons and logistic regression analysis adjusting for vascular risk 
factors, grade of stenosis, antithrombotic and statin pretreatment were applied. In sCS-patients 
higher plasma-levels of Fractalkine  (CX3CL1), IFN-α2, IL-1β, IL-2, IL-3, IL-7 were found compared to 
aCS-patients. CXCR4-expression on inflammatory cells was more evident in sCS- compared to aCS-
plaques and was associated with vulnerability-criteria. In contrast, plasma-cytokine-levels were not 
related to CXCR4-expression or other vulnerability-criteria or MES. However, in both groups distinct 
inter-cytokine correlation patterns, which persisted at follow-up and were more pronounced in the 
sCS-group could be detected. In conclusion, we identified a distinct cytokine/chemokine-network in 
sCS-patients with elevated and closely correlated mediators of diverse functions.
Approximately 10–15% of ischaemic strokes and transient ischaemic attacks (TIA) are attributable to thrombo-
embolism due to ipsilateral carotid artery  stenosis1. Carotid endarterectomy (CEA) or Carotid Artery Stenting 
(CAS) are recommended for secondary stroke prevention in patients with symptomatic carotid stenosis (sCS)2. In 
patients with asymptomatic carotid stenosis (aCS) indication for prophylactic CEA is controversial, since stroke 
rates are similar compared to best medical  treatment3. Therefore, the identification of patients with aCS who are 
at a higher risk for stroke is crucial in order to select a subgroup that benefits from primary preventive surgery.
Broad evidence exists that in-plaque inflammation is associated with a higher risk of plaque destabilisa-
tion, rupture and subsequent risk for thromboembolism—a state often referred to as “vulnerable”4. Circulating 
cytokines are important mediators of inflammatory cell influx into the vessel wall and thus crucial in atheroscle-
rotic disease  burden5. When plaque rupture occurs, platelets attach to sub-endothelial matrix molecules at the 
lesion side, followed by further coagulation  pathways6. Again, inflammatory cytokines play an important role 
in this atherothrombotic  process6,7. In particular, inflammation serves as a trigger for coagulation, while acti-
vated platelets also secrete cytokines in terms of a self-reinforcing  process8. Deeper knowledge of the thrombo-
inflammatory processes associated with cerebrovascular events in patients with carotid artery stenosis might 
lead to novel diagnostic as well as therapeutic  strategies8. Previous studies rather focused on the identification of 
novel biomarkers of plaque vulnerability in previously asymptomatic stenoses and less on possible associations 
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with the occurrence of actual neurological symptoms due to CS. In this study, we therefore aimed to investigate 
patients with aCS and sCS in order to identify a cytokine pattern that is associated with symptomatic state or 
with characteristics of plaque vulnerability in order to establish a biomarker-based approach for risk stratifica-
tion in patients with CS.
Methods
Study population. Between July 2017 and June 2018 50 patients with aCS or sCS planned for CEA were 
prospectively recruited at the Department of Neurology and the Department of Cardiothoracic-, Transplanta-
tion- and Vascular Surgery at Hannover Medical School. A carotid stenosis was defined as “symptomatic” after 
exclusion of competing stroke etiologies if an ischaemic stroke, a transient ischaemic attack (TIA), amaurosis 
fugax or central retinal artery occlusion occurred in the territory of the affected artery. Stroke diagnostics includ-
ing cranial computed tomography (CCT) and/or magnetic resonance imaging (MRI), CT or MR angiography, 
transthoracic or transesophageal echocardiography, cardiac rhythm monitoring for at least 24 h and Doppler/
duplex ultrasound were performed in all patients with sCS. Further exclusion criteria in the whole collective 
were acute infections, immunological disease, immunosuppressive therapy or current malignant disease. The 
study was approved by the ethics committee at Hannover Medical School (Ethics vote no. 7484-2017) and per-
formed according to the ethical principles of the Declaration of Helsinki. All patients gave written informed 
consent before being included in the study.
Clinical data. Patients’ demographical and clinical data were collected following a standardised interview 
including cardiovascular risk factors that were subsumed in the Essen Stroke Risk Score (ESRS), degree of 
carotid artery stenosis and current medication. On admission, stroke severity was quantified by the National 
Institutes of Health Stroke Scale (NIHSS) in sCS patients. Carotid artery stenosis was detected in cervical MR- 
or CT-angiography as well as duplex ultrasound and classified according to the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET)  criteria9. Degree of stenosis was defined as moderate (50–69%), severe 
(70–90%) or highly severe (> 90%). The clinical outcome was assessed three months after the date of surgery in 
a follow-up examination using the NIHSS and modified Rankin Scale (mRS).
Transcranial Doppler monitoring. Thirty-four patients with sufficient transtemporal window underwent 
a standardised preoperative transcranial Doppler monitoring of the ipsilateral middle cerebral artery (MCA) 
according to the criteria of the Consensus on Microembolus Detection by  TCD10. The MCA was insonated via 
the transtemporal window in 45 to 55 mm depth using a 2-MHz transducer. Monitoring was recorded up to 1 h 
unless it had to be stopped earlier due to patients’ incompliance. Microembolic signals (MES) were identified 
visually and audibly by an investigator blinded to clinical data.
Biomarkers. Peripheral venous blood was drawn prior to surgery to minimize the influence of possible 
post-ischaemic neuroinflammation. Additionally, blood was drawn at a 3 months follow-up. Specimens were 
centrifuged at 3000g for 15 min and plasma stored at − 80 °C for further analysis. Cytokines and chemokines 
were quantified using Luminex-based MILLIPLEX MAP Human Cytokine and Human sepsis Panels (Merck 
Millipore, Darmstadt, Germany) in EDTA-Plasma according to the manufacturer’s instructions. The following 
biomarkers were considered for analysis: Epidermal growth factor (EGF), Fibroblast growth factor 2 (FGF-2), 
Eotaxin (CCL11), Transforming growth factor alpha (TGF-α), Granulocyte colony stimulating factor (G-CSF), 
Granulocyte macrophage colony stimulating factor (GM-CSF), Fractalkine  (CX3CL1), Interferon alpha 2 (IFN-
α2), Interferon gamma (IFN-γ), Growth regulated oncogene (GRO-α, CXCL1), Interferon gamma induced 
protein 10 (IP-10, CXCL10), Macrophage derived chemokine (MDC, CCL22), Interleukin-12p70 (IL-12p70), 
Soluble CD40-ligand (sCD40L), Interleukin-17A (IL-17A), Interleukin-1 receptor antagonist (IL-1RA), Inter-
leukin-1 alpha (IL-1α), Interleukin-1 beta (IL-1β), Interleukin-2 (IL-2), Interleukin-3 (IL-3), Interleukin-4 (IL-
4), Interleukin-5 (IL-5), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8, CXCL8), Interleukin-9 
(IL-9), Interleukin-10 (IL-10), Interleukin-13 (IL-13), Interleukin-15 (IL-15), Monocyte chemotactic protein 1 
(MCP-1, CCL2), Monocyte chemotactic protein 3 (MCP-3, CCL7), Macrophage inflammatory protein 1 alpha 
(MIP-1α, CCL3), Macrophage inflammatory protein 1 beta (MIP-1β, CCL4), Tumor necrosis factor alpha (TNF-
α), FMS-like tyrosine kinase-3 ligand (Flt-3L), Interleukin-12p40 (IL-12p40), Macrophage inhibitory factor 
(MIF), Tissue plasminogen activator inhibitor (tPAI), Soluble intercellular adhesion molecule-1 (sICAM-1), 
Soluble vascular adhesion molecule 1 (sVCAM-1). Standard curves and concentrations were calculated with 
Bio-Plex-Manager 6.2 software (Bio-Rad Laboratories, Hercules, CA, USA).
Histological analysis. Carotid plaques from all patients were obtained after CEA and analysed at the Insti-
tute of Pathology at Hannover Medical School by an observer blinded to clinical characteristics. Specimens 
were fixed in 4% buffered formalin immediately after removal, then embedded in paraffin. 2 µm thick sections 
were cut from the tissue sections followed by histological staining using Hematoxylin and Eosin, Elastica van 
Gieson (EvG) and Periodic Acid Schiff (PAS). Immunohistochemistry was performed according to established 
protocols using anti-CXCR4 antibody (Abcam, Cambridge, MA, USA). A representative section showing maxi-
mal atherosclerotic alteration was analysed regarding the following histological criteria: intima fibrosis, lipid 
core, calcification, media degradation, acute and chronic inflammation, cholesterol crystals, neovascularization, 
intraplaque hemorrhage, fibrous cap rupture and adherent thrombus. For immunohistochemical analysis the 
number of CXCR4-positive macrophages in a 400 × high-power field (HPF) was counted, representing the area 
of maximum positive staining in each section. Furthermore, the presence of CXCR4-positivity in inflammatory 
cells was assessed as a dichotomized parameter. The count of neovessels was quantified as the median of ten 10 × 
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HPFs. We established a semiquantitative histological score containing the following items of advanced criteria of 
plaque-vulnerability: chronic inflammation, cholesterol crystals, neovascularization, intraplaque hemorrhage, 
adherent thrombus (Fig. 1). The median sum score was used as a cut off-value to stratify the samples into two 
groups, according to their individual sum of vulnerability criteria (< 2 points vs. ≥ 2 points).
Statistical analysis. Normal distribution was tested using the Kolmogorov–Smirnov test. Group differ-
ences were analysed with Student’s t test for normally distributed or Mann–Whitney U test for non-normally 
Figure 1.  Histological criteria of plaque vulnerability. Representative sections displaying criteria of the 
histological sum score. Carotid plaque, HE-staining (overview, scale bar: 2 mm) (A). Representative areas of 
different specimens showing chronic inflammation (scale bar: 200 µm) (B), cholesterol crystals (scale bar: 
400 µm) (C), neovascularization (scale bar: 200 µm) (D) intraplaque hemorrhage (scale bar: 400 µm) (E) and an 
adherent thrombus (scale bar: 500 µm) (F).
4
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21963  | https://doi.org/10.1038/s41598-020-78941-8
www.nature.com/scientificreports/
distributed data. For group comparisons the Benjamini–Hochberg procedure was applied using False Discovery 
Rate (FDR) estimation in order to correct for multiple comparisons. Chi-square test was used to compare cat-
egorical data. Binary logistic regression was done using the stepwise backwards method and included grade of 
stenosis, ESRS, antithrombotic pretreatment and statin pretreatment (i.e. treatment that was initiated before the 
event/hospitalization) as those parameters were significantly different at baseline. Correlations were calculated 
with Spearman rho test. Receiver Operating Characteristic (ROC) analysis was conducted to investigate the 
discriminative value of cytokines between groups. Statistical analysis was performed using IBM SPSS Statistics 
26 (SPSS Inc. Chicago, IL, USA). Figures were created using GraphPad Prism 5 (GraphPad Inc., La Jolla, CA, 
USA) and Gephi.
Results
Patients’ characteristics. Of 50 patients  recruited, 4 patients had to be excluded due to the following 
reasons: One patient withdrew consent, one patient was diagnosed with malignant disease and one presented 
a competing stroke etiology in stroke diagnosis. In another case the carotid plaque specimen was not collected 
leading to case exclusion. Thus, 22 patients with sCS and 24 patients with aCS were available for analysis. For 
demographic and clinical data see Table 1. Significant group differences existed regarding the following parame-
ters: coronary artery disease (p = 0.006), previous myocardial infarction (p = 0.028), degree of stenosis (p = 0.023), 
Table 1.  Patients’ demographic and clinical characteristics. P-values were calculated using Student’s t test, 
Mann–Whitney U test or Chi-square test, as appropriate. aCS asymptomatic carotid artery stenosis, BMI body 
mass index, ESRS Essen stroke risk score, CO carotid occlusion, CS carotid stenosis, NIHSS National Institutes 
of Health Stroke Scale, mRS modified Rankin Scale, Q1–Q3 quartile 1–quartile 3, sCS symptomatic carotid 
artery stenosis, SD standard deviation.
sCS aCS
p-valuen = 22 n = 24
Age (years), mean ± SD 66.27 ± 9.44 70.54 ± 9.38 0.131
Sex 0.066
Male (%) 19 (86.4) 15 (62.5)
Female (%) 3 (13.6) 9 (37.5)
BMI (kg/m2) ± SD 27.34 ± 3.37 29.38 ± 5.74 0.155
Adiposity (%) 3 (13.6) 9 (37.5) 0.066
ESRS on admission (Q1-Q3) 3 (2–4) 4 (4–5) 0.002
ESRS at 90 days (Q1-Q3) 4 (3–4) 4 (4–5) 0.083
Hypertension (%) 16 (72.7) 21 (87.5) 0.207
Diabetes mellitus (%) 5 (22.7) 8 (33.3) 0.425
Dyslipoproteinemia (%) 18 (81.8) 19 (79.2) 0.821
Peripheral arterial disease (%) 2 (9.1) 7 (29.2) 0.086
Nicotine abuse (%) 17 (77.3) 19 (79.2) 0.881
Alcohol abuse (%) 4 (18.2) 5 (20.8) 0.821
Coronary artery disease (%) 2 (9.1) 11 (45.8) 0.006
Previous myocardial infarction (%) 1 (4.5) 7 (29.2) 0.028
Atrial fibrillation (%) 0 (0) 2 (8.3) 0.166
Previous stroke (%) 3 (13.6) 5 (20.8) 0.520
Dementia (%) 0 (0) 1 (4.2) 0.333
Epilepsy (%) 2 (9.1) 1 (4.2) 0.499
Medication
Antithrombotic pretreatment (%) 9 (40.9) 23 (95.8) < 0.001
Statin pretreatment (%) 8 (36.4) 18 (75.0) 0.008
NIHSS on admission (Q1–Q3) 0 (0–2) N.A
NIHSS 90 days (Q1–Q3) 0 (0–1) N.A
mRS 90 days (Q1–Q3) 0 (0–1.25) N.A
Grade of stenosis 0.023
Moderate 1 (4.5) 0 (0)
Severe 10 (45.5) 20 (83.3)
Highly severe 11 (50.0) 4 (16.7)
Contralateral CS 13 (59.1) 8 (33.3) 0.08
Contralateral CO 1 (4.5) 3 (12.5) 0.339
Time from ischaemic event to blood collection (days) (Q1–Q3) 8 (3.5–12) N.A
Time to follow-up (days) (Q1–Q3) 92 (90–104) 97 (91–104) 0.234
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ESRS (p = 0.002), antithrombotic pretreatment (p < 0.001) and statin pretreatment (p = 0.008), with more severe 
stenosis, increased morbidity and intensified medication in asymptomatic patients. In the sCS group 7 patients 
had transient symptoms, 4 patients suffered central retinal artery occlusion. Likewise, stroke severity was low 
with a median NIHSS of 0. The median time difference between ischaemic event and preoperative blood collec-
tion was 8 days in the sCS group. Three patients declined the follow-up examination. The median time to follow-
up was 95 days and did not significantly differ between the groups (p = 0.234).
Microembolic signals. TCD monitoring was performed in 34 patients. Reasons for missing TCD-monitor-
ing were missing written consent for this examination (n = 2), absent temporal window (n = 5), emergency oper-
ation (n = 2) and incompliance leading to discontinuation (n = 3). Symptomatic patients showed a range of 0–13 
MES/h with a median count of 0 MES/h, asymptomatic patients showed a range of 0–2 MES/h with a median 
count of 0 MES/h (p = 0.707). The count of MES per hour did not correlate with plasma cytokine concentrations. 
In addition, we divided the study cohort into two groups: Patients with MES at baseline (MES+) and patients 
without MES (MES−). We did not find group differences regarding cytokine levels or histological features.
Preoperative biomarker levels. At baseline, in total 44 samples were available. For the follow-up 42 
samples could be analysed. Due to many values below minimum detection levels following analytes needed 
to be excluded from further analysis: Flt3L, MCP-3, IL-12p40, IL13, IL-1α, IL-9, IL-6, TNF-b, VEGF, leaving 
33 analytes for further analysis. Results of biomarker analysis are listed in Table 2. In univariable analysis of 
preoperative samples sCS-patients had significantly higher plasma concentrations of the following cytokines 
than aCS-patients regarding preoperative blood samples: EGF (p = 0.029), FGF2 (p = 0.032), TGF-α (p = 0.034), 
GM-CSF (p = 0.023), Fractalkine  (CX3CL1) (p < 0.001), IFN-α2 (p = 0.003), IFN-γ (p = 0.038), IL-1β (p = 0.007), 
IL-2 (0.010), IL-3 (p = 0.006), IL-5 (p = 0.040), IL-7 (p = 0.002), IL-8/CXCL8 (p = 0.009), IL-10 (p = 0.037), IL-15 
(p = 0.018), IL-17A (p = 0.019), MIP-1α/CCL3(p = 0.020). Additionally, a non-significant difference by trend 
existed for GRO-α/CXCL1 (p = 0.082) and G-CSF (p = 0.081). After applying Benjamini–Hochberg procedure 
and binary logistic regression analysis adjusted for degree of stenosis, ESRS, antithrombotic pretreatment and sta-
tin pretreatment following markers remained significantly different: Fractalkine (p = 0.036), IFN-α2 (p = 0.023), 
IL-1β (p = 0.025), IL-2 (p = 0.023), IL-3 (p = 0.030) and IL-7 (p = 0.029) (Fig. 2). ROC-analysis revealed following 
areas under the curve (AUC): Fractalkine/CX3CL1: 0.806, IFN-α2: 0.758, IL-1β: 0.738, IL-2: 0.725, IL-3: 0.743, 
IL-7: 0.769.
All cytokines with significant differences in binary logistic regression analysis showed a positive correlation 
to concentrations in the follow-up sample at 90 days [IL-2 (p < 0.001, r = 0.530), IFN-α2 (p < 0.001, r = 0.565), 
Fractalkine/CX3CL1 (p = 0.009, r = 0.408), IL-1β (p = 0.002, r = 0.467), IL-3 (p = 0.001, r = 0.499), IL-7 (p = 0.022, 
r = 0.362)]. See supplemental table S2A and B for inter-cytokine correlations in preoperative samples.
Biomarker levels at 90 days follow-up. The univariable analysis revealed significantly higher plasma lev-
els in patients with sCS at 90 days for the following markers: EGF (p = 0.010), IFN-a2 (p = 0.043), IL-3 (p = 0.030), 
IL-7 (p = 0.030). A trend towards higher levels could be detected for Fractalkine (p = 0.071), TGF-α (p = 0.075), 
G-CSF (p = 0.080), GM-CSF (p = 0.090), IL-5 (p = 0.063), IL-10 (p = 0.082) and sCD40L (p = 0.091). These group 
differences did not sustain to be significantly different after Benjamini–Hochberg-procedure and binary logistic 
regression analysis. However, there were distinct inter-cytokine correlation patterns in both groups which are 
visualised using Force-directed graphs in Fig. 3. For detailed information see the heat map of inter-cytokine cor-
relations in the supplemental tables S2C and D.
Histological analysis. The histological sum score was associated with presence of arterial hyperten-
sion (p = 0.013) and dyslipoproteinemia (p = 0.013) but did not show a group difference between sCS and aCS 
(p = 0.985). There were no significant differences between sCS and aCS regarding the investigated histological 
features. For detailed results of the histological analysis see supplemental table  S1. Moreover, no differences 
regarding circulating biomarker concentrations were found between patients with plaques exhibiting more or 
less vulnerability criteria.
Immunohistochemistry revealed a significant difference for CXCR4-positive inflammatory cells in sCS com-
pared to aCS (p = 0.034) (Fig. 4A–C). CXCR4-positivity on inflammatory cells was moreover associated with 
a higher histological sum score (p = 0.018) (Fig. 4D). In particular, CXCR4-positive inflammatory cells were 
related to a larger lipid core (p = 0.027) and chronic inflammation (p = 0.006). An association by trend existed 
for intraplaque hemorrhage (p = 0.053) which was more often present in plaques with CXCR4-positive inflam-
matory cells. There was no association between CXCR4-positivity and plasma cytokine levels nor an association 
between cytokine plasma concentrations and the histological sum score.
Discussion
Cytokine mediated inflammatory mechanisms are crucial in atherosclerotic plaque vulnerability as well as in 
atherothrombosis. Targeting inflammatory biomarkers is a promising strategy in preventive treatment of vascular 
 disease11. Indeed, the inhibition of IL-1β by Canakinumab investigated in the Canakinumab Antiinflammatory 
Thrombosis Outcome Study (CANTOS) trial led to a significant reduction of vascular events in patients with 
previous myocardial  infarction12. Detailed knowledge of the mediators involved in the occurrence of cerebro-
vascular events is therefore of high interest. Previous studies focused on inflammatory markers within the 
atherosclerotic plaque and revealed distinct cytokine signatures associated with plaque  vulnerability13. Like-
wise, numerous studies investigated circulating biomarkers regarding presence of carotid stenosis or measures 
of cerebrovascular  risk14. The question remains whether systemic inflammatory markers appropriately reflect 
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Preoperative sample [median 
(Q1–Q3)]
12.44 (03.08–26.12) 1.25 (1.25–16.1) 0.029 0.048
90 days follow-up sample 
[median (Q1–Q3)]
21.78 (11.42–62.14) 9.76 (2.81–20.77) 0.010 0.114
FGF-2 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
46.28 (30.13–63.88) 31.25 (21.37–49.51) 0.032 0.016
90 days follow-up sample 
[median (Q1–Q3)]
45.44 (30.10–61.89) 28.94 (21.37–54.06) 0.134 0.150
Eotaxin (pg/ml)
preoperative sample [median 
(Q1–Q3)]
67.38 (41.91–85.13) 48.59 (35.24–88.56) 0.806 0.124
90 days follow-up sample 
[median (Q1–Q3)]
69.09 (45.38–94.37) 61.88 (42.36–87.15) 0.809 0.282
TGF-α (pg/ml)
preoperative sample [median 
(Q1–Q3)]
0.56 (0.41–0.79) 0.30 (0.22–0.70) 0.034 0.669
90 days follow-up sample 
[median (Q1–Q3)]
0.54 (0.34–0.67) 0.32 (0.15–0.55) 0.075 0.697
G-CSF (pg/ml)
preoperative sample [median 
(Q1–Q3)]
11.45 (2.38–26.52) 2.38 (2.38–22.75) 0.081 0.727
90 days follow-up sample 
[median (Q1–Q3)]
22.75 (11.99–37.92) 10.65 (4.53–29.68) 0.080 0.225
GM-CSF (pg/ml)
preoperative sample [median 
(Q1–Q3)]
4.71 (1.48–7.67) 2.11 (0.22–4.05) 0.023 0.025
90 days follow-up sample 
[median (Q1–Q3)]
5.04 (1.55–9.34) 2.43 (1.47–5.28) 0.090 0.082
Fractalkine (pg/ml)
preoperative sample [median 
(Q1–Q3)]
75.89 (56.70–93.17) 45.99 (19.91–56.70) < 0.001 0.036
90 days follow-up sample 
[median (Q1–Q3)]
71.25 (56.70–101.30) 64.17 (34.07–93.17) 0.071 0.245
IFN-α2 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
25.81 (7.33–45.50) 3.36 (3.36–21.23) 0.003 0.023
90 days follow-up sample 
[median (Q1–Q3)]
23.52 (8.79–44.19) 10.60 (3.36–25.81) 0.043 0.056
IFN-γ (pg/ml)
preoperative sample [median 
(Q1–Q3)]
8.95 (2.61–11.98) 3.71 (0.78–7.07) 0.038 0.632
90 days follow-up sample 
[median (Q1–Q3)]
7.26 (1.97–9.52) 4.09 (1.51–8.95) 0.421
GRO-α (pg/ml)
preoperative sample [median 
(Q1–Q3)]
695.62 (416.49–1138.17) 476.72 (239.53–875.61) 0.082 0.393
90 days follow-up sample 
[median (Q1–Q3)]
610.18 (368.58–1319.76) 965.39 (513.93–1337.75) 0.388 0.451
IP-10 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
330.00 (286.24–599.50) 397.59 (253.04–464.90) 0.378 0.735
90 days follow-up sample 
[median (Q1–Q3)]
288.95 (216.34–642.74) 441.40 (308.93–671.78) 0.155 0.860
MDC (pg/ml)
preoperative sample [median 
(Q1–Q3)]
420.80 (318.65–473.98) 425.40 (313.56–564.65) 0.838 0.176
90 days follow-up sample 
[median (Q1–Q3)]
466.21 (341.28–556.46) 449.37 (265.08–611.50) 0.739 0.532
IL-12p70 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
0.09 (0.09–0.98) 0.09 (0.09–0.67) 0.412 0.985
90 days follow-up sample 
[median (Q1–Q3)]












preoperative sample [median 
(Q1–Q3)]
123.98 (73.63–271.08) 94.96 (70.94–286.46) 0.622 0.646
90 days follow-up sample 
[median (Q1–Q3)]
165.71 (86.35–363.85) 120.04 (42.05–201.68) 0.091 0.212
IL-17A (pg/ml)
preoperative sample [median 
(Q1–Q3)]
2.31 (1.37–2.58) 1.33 (0.89–2.06) 0.019 0.763
90 days follow-up sample 
[median (Q1–Q3)]
2.21 (0.72–3.10) 1.18 (0.75–2.32) 0.262 0.745
IL-1RA (pg/ml)
preoperative sample [median 
(Q1–Q3)]
5.22 (1.15–17.77) 2.44 (0.02–7.79) 0.142 0.103
90 days follow-up sample 
[median (Q1–Q3)]
5.95 (0.02–13.49) 3.13 (0.02–7.80) 0.445 0.087
IL-1β (pg/ml)
preoperative sample [median 
(Q1–Q3)]
1.28 (0.72–1.68) 0.56 (0.31–1.00) 0.007 0.025
90 days follow-up sample 
[median (Q1–Q3)]
1.35 (0.54–1.71) 0.76 (0.40–1.64) 0.177 0.261
IL-2 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
1.13 (0.78–1.75) 0.78 (0.66–1.01) 0.010 0.023
90 days follow-up sample 
[median (Q1–Q3)]
1.48 (0.95–1.95) 1.01 (0.66–1.75) 0.186 0.644
IL-3 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
1.49 (0.90–2.38) 0.75 (0.36–1.35) 0.006 0.030
90 days follow-up sample 
[median (Q1–Q3)]
1.79 (0.80–2.25) 1.05 (0.48–1.47) 0.030 0.082
IL-4 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
6.27 (0.90–23.94) 0.9 (0.9–18.35) 0.505 0.699
90 days follow-up sample 
[median (Q1–Q3)]
11.83 (5.62–23.25) 14.21 (0.90–41.94) 0.808 0.397
IL-5 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
0.47 (0.08–1.06) 0.15 (0.05–0.32) 0.040 0.024
90 days follow-up sample 
[median (Q1–Q3)]
0.63 (0.12–1.11) 0.22 (0.05–0.52) 0.063 0.391
IL-7 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
2.70 (1.69–3.32) 0.78 (0.09–2.04) 0.002 0.029
90 days follow-up sample 
[median (Q1–Q3)]
3.22 (1.19–4.20) 1.45 (0.09–3.12) 0.030 0.162
IL-8 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
2.88 (2.13–4.06) 1.69 (1.13–2.76) 0.009 0.769
90 days follow-up sample 
[median (Q1–Q3)]
3.09 (1.82–4.53) 2.78 (1.35–3.55) 0.461 0.547
IL-10 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
0.38 (0.12–1.98) 0.12 (0.12–0.25) 0.037 0.111
90 days follow-up sample 
[median (Q1–Q3)]
0.25 (0.00–2.43) 0.00 (0.00–0.38) 0.082 0.799
IL-15 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
0.77 (0.24–2.22) 0.24 (0.02–0.77) 0.018 0.044
90 days follow-up sample 
[median (Q1–Q3)]
1.03 (0.35–2.47) 0.62 (0.35–1.55) 0.408 0.199
MCP-1 (pg/ml)
preoperative sample [median 
(Q1–Q3)]
390.21 (250.25–490.61) 363.80 (284.93–470.04) 0.812 0.943
90 days follow-up sample 
[median (Q1–Q3)]
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local plaque  inflammation15,16 or rather an atherothrombotic event leading to cerebrovascular symptoms. To 
answer this question, we chose a comprehensive approach in order to identify a systemic cytokine pattern that 
is associated with characteristics of vulnerability or with the occurrence of ischaemic cerebrovascular events in 
carotid artery stenosis.
The analysis of patients’ baseline characteristics revealed significant differences regarding cardiovascular 
risk factors as well as antithrombotic and statin pretreatment, which were more common in patients with aCS. 
Due to preexisting cardiovascular diseases such as former coronary artery disease or myocardial infarction, 
these patients probably underwent more intensive prophylactic diagnostics in terms of check-up examinations, 
which lead to the diagnosis of aCS at an early and so far asymptomatic state. Compared to sCS patients with so 
far undiagnosed carotid artery stenosis and thus missing medical pretreatment, the asymptomatic group was 
also more likely to receive optimised medical treatment i.e. antithrombotic as well as lipid lowering therapy at 
baseline. This underscores the importance of risk stratification in terms of primary prevention. In sCS patients, 
moreover, male sex tended to be more prevalent than in aCS patients. This is in line with previous reports showing 
that carotid plaques of female patients might feature stable and less inflammatory plaque characteristics more 
frequently than those of male  patients17.
Unexpectedly, we found no significant difference between sCS and aCS regarding the count of MES. Although 
there was a wider range of MES/h with a maximum count of 13 MES/h in sCS this difference did not reach 
statistical significance which may be due to the low rate of microembolisation and again the intensified medical 
 treatment18 which has been in most cases initiated preceding Doppler sonography. Remarkably, especially statin 
treatment was previously reported being associated with lower counts of  MES19.
The histological analysis revealed no significant group differences concerning established features of plaque 







preoperative sample [median 
(Q1–Q3)]
4.41 (2.67–5.48) 0.83 (0.48–4.70) 0.020 0.107
90 days follow-up sample 
[median (Q1–Q3)]
3.95 (0.83–5.63) 3.08 (0.83–4.96) 0.367 0.885
MIP-1β (pg/ml)
preoperative sample [median 
(Q1–Q3)]
24.95 (11.94–32.76) 21.28 (15.51–26.09) 0.417 0.826
90 days follow-up sample 
[median (Q1–Q3)]
26.37 (3.81–33.36) 18.56 (15.51–27.62) 0.582 0.767
TNF-α (pg/ml)
preoperative sample [median 
(Q1–Q3)]
15.73 (12.77–17.84) 15.52 (11.81–18.79) 0.944 0.332
90 days follow-up sample 
[median (Q1–Q3)]
15.75 (10.76–19.66) 14.62 (12.18–18.42) 0.849 0.365
MIF (pg/ml)
preoperative sample [median 
(Q1–Q3)]
320.87 (238.10–452.86) 252.14 (195.26–452.89) 0.165 0.332
90 days follow-up sample 
[median (Q1–Q3)]
381.03 (245.09–751.89) 320.87 (245.09–491.43) 0.285 0.936
tPAI (ng/ml)
preoperative sample [median 
(Q1–Q3)]
73.74 (46.99–113.98) 68.67 (57.23–85.23) 0.422 0.252
90 days follow-up sample 
[median (Q1–Q3)]
77.72 (49.36–97.36) 58.61 (37.94–81.31) 0.157 0.149
sICAM-1 (ng/ml)
preoperative sample [median 
(Q1–Q3)]
180.88 (151.20–222.83) 155.02 (136.44–205.24) 0.285 0.806
90 days follow-up sample 
[median (Q1–Q3)]
184.08 (138.59–269.17) 170.56 (157.21–201.75) 0.666 0.769
sVCAM-1 (ng/ml)
preoperative sample [median 
(Q1–Q3)]
562.26 (414.00–703.18) 462.06 (377.61–579.36) 0.144 0.381
90 days follow-up sample 
[median (Q1–Q3)]
571.25 (470.25–600.32) 565.78 (450.10–677.52) 0.542 0.380
Table 2.  Comparison of biomarker concentrations in patients with symptomatic and asymptomatic carotid 
stenosis. P-values were calculated using Student’s t test or Mann–Whitney U test as appropriate and binary 
logistic regression analysis adjusted for grade of stenosis, ESRS antithrombotic pre-treatment and statin pre-
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advanced atherosclerotic disease and thus could feature a vulnerable plaque, even if this was so far not symp-
tomatic. However, in the immunohistochemical staining, we detected a group difference regarding presence of 
CXCR4-positive inflammatory cells which were more prevalent in sCS plaques. This is clearly in line with a pre-
vious work by our group in which we investigated carotid plaque specimens by autoradiography using the 68Ga-
Pentixafor tracer which specifically binds to  CXCR420. Consistently, we now could prove that CXCR4-presence 
is associated with known characteristics of plaque vulnerability. Merckelbach et al. reported a higher CXCR4-
expression in advanced atherosclerotic plaques and that CXCR4 is predominantly expressed in  macrophages21. 
While its specific function in atherosclerosis remains  controversial22 targeting CXCR4 using molecular imaging 
might thus constitute a promising diagnostic strategy. In line with this, clinical positron emission tomography 
using 68Ga-Pentixafor was already evaluated in atherosclerotic diseases for the purpose of plaque  imaging20,23.
Figure 2.  Differences of cytokine concentrations between patients with symptomatic and asymptomatic carotid 
stenosis. Boxplots depicting a comparison of plasma cytokine levels in patients with symptomatic (sCS) and 
asymptomatic carotid stenosis (aCS). After correction for multiple comparisons and adjustment for possible 
confounders significant differences were observed concerning Fractalkine (A), IFN-α2 (B), IL-1β (C), IL-2 (D), 
IL-3 (E), IL-7 (F). Asterisks refer to univariable analysis (***p < 0.001; **p < 0.01; *p < 0.05).
Figure 3.  Inter-cytokine correlation networks in symptomatic and asymptomatic carotid stenosis. Force-
directed graphs using Fruchtermann–Reingold-Algorithm depicting plasma inter-cytokine correlations in 
symptomatic (A) and asymptomatic (B) carotid stenosis at 90 days follow-up.
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The main finding of this study is the identification of a distinct cytokine pattern with significantly elevated 
plasma levels in sCS compared to aCS patients. After correction for multiple comparisons and adjustment 
for degree of stenosis, ESRS, antithrombotic pretreatment and statin pretreatment significant differences were 
observed for Fractalkine, IFN-α2, IL-1β, IL-2, IL-3 and IL-7. It is important to note that in this study we have 
placed particular emphasis on avoiding influence by stroke-induced inflammation. In the sCS group the median 
NIHSS was 0, seven patients had transient symptoms, and four patients suffered central retinal artery occlusion. 
Thus, influence on cytokine levels due to an inflammatory response by cerebral infarction is very unlikely. All of 
the mediators found to be significantly elevated have previously been implicated in cardiovascular disorders and 
were to some extent already tested in pre-clinical and clinical studies using antagonising antibodies.
The most prominent representative is probably IL-1β for which there is broad evidence regarding its role 
in atherosclerosis (for a review  see24). As described above, IL-1β-antagonisation led to a significant reduction 
of vascular events in atherosclerotic diseased patients in the CANTOS-trial12. Additionally, IL-1β is suspected 
to support prothrombotic  states25 and leads to platelet activation. Those platelets in turn secrete IL-1β26 which 
plays a fundamental role in adhesion to endothelial  cells27. Thus, our result of an independent elevation of IL-1β 
in patients with sCS is clearly in line with the current evidence. However, clinical data on targeting IL-1β for the 
purpose of secondary stroke prevention are lacking so far.
Elkind et al. reported an independent association of IL-2 levels with carotid intima-media-thickness28. Oth-
ers showed that treatment using an IL-2/anti-IL-2 monoclonal antibody (mAb) attenuates atherosclerosis via 
expansion of regulatory T cells (Tregs)29 and evidence exists that also Type 2 innate lymphoid cells might play 
an important role in IL-2 mediated reduction of  atherosclerosis30. In summary it is postulated that IL-2 leads 
to secretion of IL-10 and TGF-β by regulatory T cells and independent secretion of IL-5 and IL13 by innate 
lymphoid cells, resulting in an overall reduction of plaque  inflammation30. Thus, it will be interesting to see if 
immunomodulation via IL-2 might emerge as a potential therapy to limit atherosclerotic  acceleration31.
IL-7 is a crucial mediator of T cell development and is contributing to endothelial inflammation via inducing 
monocyte  recruitment32. Previously, Damås et al. showed an elevation of IL-7 levels in patients with unstable 
angina pectoris compared to patients with stable angina pectoris and  controls33. Besides colony stimulating fac-
tors like G-CSF or GM-CSF, IL-3 is thought to stimulate haematopoiesis, especially in emergent settings (i.e. the 
differentiation of myeloid cells upon infection or inflammation)34. Robbins et al. reported that IL-3 and GM-CSF 
promote extramedullary differentiation of haematopoietic stem and progenitor cells to inflammatory monocytes 
which infiltrate and aggravate atherosclerotic  lesions35. Of note, in our correlation analysis IL-3 was strongly 
associated with GM-CSF levels in both sCS and aCS patients. Unsurprisingly, GM-CSF did exhibit higher values 
in the sCS group. However, after Benjamini–Hochberg-correction this difference was not considered statistically 
significant. Because of its distinct functions in haematopoiesis and constitutive effects of immune cell influx in 
atherosclerosis, IL-3 might represent another therapeutic  target36. Our results now indicate for the first time that 
these properties might be relevant for cerebrovascular events in patients with carotid stenosis.
Much less evidence about its inert biological function is available for IFN-α2 and our study is the first 
implicating this cytokine in carotid artery disease. However, IFN-α2 levels have previously been investigated in 
Figure 4.  CXCR4-staining and relation to groups and criteria of plaque vulnerability. Exemplary CXCR4-
staining of carotid plaque specimens of a sCS patient (scale bar: 400 µm) (A) and an aCS patient (scale bar: 
400 µm) (B) indicating presence of CXCR4-positive inflammatory cell infiltrations in (A). Differential presence 
of CXCR4-positive inflammatory cells regarding groups (C) and histological sum score (D).
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auto-immunological, haematological diseases and viral  infections37. In cancer therapy, IFN-α2 leads to pericyte 
mediated vessel maturation and consequent  stabilisation38. As we have previously shown that pericytes promote 
vascular stability in a model of atherosclerotic  disease39, it will be interesting to investigate this interrelation in 
the future, in particular as IFN-based therapy was independently associated with reduced stroke risk in Hepatitis 
C  patients40.
Fractalkine is a unique representative of chemokines in several respects. It exists in a soluble and membrane-
bound form and fulfills chemotactic and adhesive functions for several inflammatory cell populations, especially 
 monocytes41. In previous studies Fractalkine was implicated in atheroma growth and suspected to contribute 
to formation of platelet-monocyte aggregates suggesting a detrimental role in atherosclerotic  diseases41,42. By 
contrast, Getzin et al. showed that Fractalkine and its receptor,  CX3CR1, are involved in regeneration of the 
endothelium after arterial injury via recruitment of non-classical  monocytes43. In concordance to these rather 
beneficial properties experimental studies identified Fractalkine as being neuroprotective in different brain 
 disorders44,45, including  stroke46. Likewise, we and others described an inverse association of Fractalkine/CX3CL1 
dynamics with clinical severity and outcome in stroke  patients47,48. Thus, it remains elusive whether the signifi-
cant elevation of Fractalkine levels in this study is to be interpreted as primarily hazardous or as compensatory 
regenerative mechanism. In a previous study, we investigated monocyte subsets and related chemokines, i.e. 
Fractalkine/CX3CL1 and MCP-1/CCL2, in patients with sCS, aCS or cardioembolic  stroke
49. In contrast to our 
current findings, in the previous study we observed different levels of MCP-1/CCL2, but not of Fractalkine/
CX3CL1. These divergent results could originate from the inclusion of patients with higher stroke severity in 
the previous study, whereas we abstained from this as far as possible in the current study for the reasons stated 
above. Of note, MCP-1/CCL2 was recently identified as biomarker of stroke risk in a large meta-analysis50. The 
role of MCP-1/CCL2 in atherosclerosis is meanwhile clearly  established51. Thus, one might speculate that MCP-1/
CCL2 increase might be less attributable to atherothrombosis than to cerebral tissue damage, as also murine 
stroke studies  suggest52.
We did not find any association of circulating cytokines with histological features of plaque vulnerability or 
with MES. After correction for multiple comparisons no significant group differences in plasma biomarker levels 
could be observed at the three months follow-up. Thus, it seems very likely that the biomarker changes presented 
are attributable to the atherothrombotic event rather than to plaque vulnerability. However, the inter-cytokine 
correlation analysis revealed a distinct network of markers that was remarkably divergent between groups also 
at follow-up. This potentially indicates a persisting systemic pro-inflammatory milieu in sCS patients which in 
turn may contribute to an increased vascular  risk5. In order to further investigate this hypothesis, we propose 
longitudinal biomarker studies in patients with significant carotid atherosclerosis to evaluate the prognostic 
value of the presented cytokines. If the hypothesis that the network patterns presented might constitute a risk 
factor for atherothrombotic events in carotid stenosis, this would be of interest not only for diagnostic, but also 
for therapeutic purposes.
This study has several limitations. We comprehensively characterised patients resulting in a large dataset in a 
relatively small sample size. Although, we applied corrections for multiple comparisons and logistic regression 
analysis, according studies with larger sample sizes are clearly warranted to validate our findings. Since this is 
an observational study, we are not able to conclude any causal relation of the biomarkers with clinical endpoints 
but only associations.
Conclusions
In conclusion, in our analysis adjusted for vascular risk factors, grade of stenosis, antithrombotic and statin 
pretreatment we identified distinct cytokines being elevated in patients who suffered cerebrovascular events due 
to carotid stenosis. Of note, these mediators exhibit various functions concerning atherosclerotic inflammation, 
platelet activation or inflammatory cell recruitment and haematopoiesis. While we did not find an association 
of these circulating biomarkers with features of plaque vulnerability, presence of CXCR4-positive inflammatory 
cells was associated both with sCS and vulnerability characteristics. However, systemic inter-cytokine correlations 
were distinct and pronounced in sCS compared with aCS patients even at a three months follow-up, probably 
indicating a persisting pro-inflammatory milieu. Further, larger and longitudinal studies are warranted in order 
to clarify the diagnostic and therapeutic value of the mediators presented.
Data availability
The datasets generated during and analysed during the current study are available from the corresponding author 
on reasonable request.
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